Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inamed SEC probe update

This article was originally published in The Gray Sheet

Executive Summary

Securities and Exchange Commission staffers recommend halting the investigation of Inamed's disclosures for its silicone gel-filled breast implants, after advising that no enforcement action be taken, the firm reports in a Nov. 9 10-K filing. The firm has repeatedly claimed it is in compliance with federal securities laws since the probe began in February (1"The Gray Sheet" March 21, 2005, In Brief)...

You may also be interested in...



SEC investigation targets Inamed

Adequacy of disclosures concerning firm's silicone gel-filled breast implants is under Securities and Exchange Commission review, Inamed reports in 10-K filing March 16. "We believe that our disclosures regarding our silicone gel-filled breast implant products have been and are in compliance with federal securities laws," Inamed maintains, adding that those disclosures represent $3.4 mil., or less than 1% of its 2004 revenue. FDA's General & Plastic Surgery Devices Panel is slated to consider Inamed and Mentor's respective silicone gel breast implant premarket applications April 11-13 (1"The Gray Sheet" March 7, 2005, In Brief)...

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

UsernamePublicRestriction

Register

MT022901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel